Sudeep Pharma Private Limited’s promoters have completed the acquisition of shares from their joint venture partners, JRS PHARMA, regaining 100% ownership of the company—representing a significant step in Sudeep Pharma’s ongoing growth and development, enabling the company to pursue its vision.

Promoters of Sudeep Pharma, Sujit Bhayani & Family, entered into a joint venture in 2015 with JRS Pharma. Combining JRS Pharma’s expertise in excipients with Sudeep Pharma’s technological advancements and robust manufacturing capabilities resulted in significant growth and valuable cooperation over the past nine years.

Sudeep Pharma remains dedicated to delivering cutting-edge pharmaceutical solutions, maintaining the highest standards of quality, and ensuring continued customer satisfaction. The company is poised to accelerate its research and development initiatives, expand its product portfolio, and pursue new opportunities.

Both Sudeep Pharma and JRS Pharma assure all stakeholders that this transaction will have no impact on current operations or product availability. Customers can expect to receive the same levels of service and product quality that both companies have consistently provided.